Loading stock data…
Oruka Therapeutics, Inc. (ORKA)
$94.31+1.80 (+1.95%)
Market ClosedLast close Sep 8
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oruka Therapeutics, Inc. in the Healthcare sector is trading at $94.31 with a market capitalization of $6.2B. Wall Street consensus targets $155.00 (12 analysts), implying a +64.4% move over the next 12 months. The stock is currently 18% below its 52-week high of $115.52, remaining 61.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +64.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 23) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.43M↓ | -$34.43M↓ | -$34.10M↓ | -$28.43M↓ | -$25.09M |
| Net Income | -$31.82M↓ | -$29.58M↑ | -$30.28M↓ | -$24.57M↓ | -$21.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.95%
Volume
Today's trading volume
867,814
Recent News
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
HMI Capital Pares Its Stake in AI Company nCino
Plus, other significant moves in holdings of Oruka Therapeutics, Enliven Therapeutics, NN, and Alvotech.
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.